Evidence map›Paper›PMID 36259028›Full record

ArticleCureus2022

Hemiparesis Revealing a Unique Neurological Hemophagocytic Lymphohistiocytosis in a Patient With Griscelli Syndrome Type 2.

Othman Moueqqit, Ghanam Ayad, Madiha Benhachem, Abdelilah Lahmar, Hiba Ramdani, Miry Nadir, Mohammed Bensalah, Amal Bennani, Imane Kamaoui, Rachid Seddik and 1 more

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Othman MoueqqitDepartment of General Medicine, Faculty of Medicine and Pharmacy of Oujda, Mohammed First University of Oujda, Oujda, MAR.
Ghanam AyadPediatric Medicine, Centre Hospitalier Universitaire (CHU) Mohammed VI Oujda, Oujda, MAR.
Madiha BenhachemDepartment of Pediatrics, Faculty of Medicine and Pharmacy of Oujda, Mohammed VI University Hospital, Mohammed First University of Oujda, Oujda, MAR.
Abdelilah LahmarDepartment of Medicine, Faculty of Medicine and Pharmacy of Oujda, Mohammed VI University Hospital, Mohammed First University of Oujda, Oujda, MAR.
Hiba RamdaniDepartment of Medicine, Faculty of Medicine and Pharmacy of Oujda, Mohammed VI University Hospital, Mohammed First University of Oujda, Oujda, MAR.
Miry NadirDepartment of Pathology, Faculty of Medicine and Pharmacy of Oujda, Mohammed VI University Hospital, Mohammed First University of Oujda, Oujda, MAR.
Mohammed BensalahDepartment of Hematology and Oncology, Faculty of Medicine and Pharmacy of Oujda, Mohammed VI University Hospital, Mohammed First University of Oujda, Oujda, MAR.
Amal BennaniDepartment of Anatomopathology, Faculty of Medicine and Pharmacy of Oujda, Mohammed VI University Hospital, Mohammed First University of Oujda, Oujda, MAR.
Imane KamaouiDepartment of Radiology, Faculty of Medicine and Pharmacy of Oujda, Mohammed VI University Hospital, Mohammed First University of Oujda, Oujda, MAR.
Rachid SeddikDepartment of Hematology, Faculty of Medicine and Pharmacy of Oujda, Mohammed VI University Hospital, Mohammed First University of Oujda, Oujda, MAR.
Noufissa BenajibaPediatric Hematology, Centre Hospitalier Universitaire (CHU) Mohammed VI Oujda, Oujda, MAR.
Mohamed I University · MACentre Hospitalier Universitaire d’Oujda · MACentre Hospitalier Universitaire Mohammed VI · MA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Griscelli syndrome (GS) is a rare genetic disorder that encompasses three different subtypes (GS type 1 (GS1), GS type 2 (GS2), and GS type 3 (GS3)), in which isolated neurological manifestations without immune system implications are typically seen in GS1, while neurological involvements in GS2 should be attributed to the macrophage and lymphocyte invasion of the central nervous system (CNS), under associated hemophagocytic lymphohistiocytosis (HLH). The presence of the clinical, biological, and hematologic features of HLH help explain the neurological defects that GS2 patients unusually present. In our case report, however, we attempt to highlight an uncommon presentation of GS2 involving a hemiparesis, along which we did not have any clinical or biological features of HLH. We also collect and evaluate similar published cases that feature this problem of explaining the neurological manifestations among GS2 patients.

Indexed as

albinismgriscelli syndromehemophagocytic lymphohistiocytosismacrophage activation syndromeseizures

Identifiers

PMID36259028
PMCPMC9573055
OpenAlexW4295682048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.